Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 6/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9553248 | 0.90 | BRS3 (0.51) | BRS3AGTR1AGTR2MMELTB4R2 | |
| SCHEMBL9738654 | 0.86 | FOLH1 (0.42) | BRS3FOLH1AGTR1AGTR2LTB4R | |
| SCHEMBL9552037 | 0.85 | AGTR1 (0.49) | FOLH1AGTR1AGTR2LTB4RLTB4R2 | |
| SCHEMBL9741307 | 0.84 | AGTR1 (0.51) | AGTR1AGTR2MME | |
| SCHEMBL9552792 | 0.83 | LTB4R (0.47) | BRS3FOLH1AGTR1AGTR2LTB4R | |
| SCHEMBL9552249 | 0.82 | BRS3 (0.49) | BRS3AGTR1AGTR2MMELTB4R2 | |
| SCHEMBL9553102 | 0.81 | BRS3 (0.52) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL9552127 | 0.81 | AGTR1 (0.54) | BRS3AGTR1AGTR2MMELTB4R2 | |
| SCHEMBL9553316 | 0.81 | FOLH1 (0.49) | FOLH1AGTR1AGTR2LTB4RLTB4R2 | |
| SCHEMBL9532242 | 0.80 | BRS3 (0.41) | BRS3FOLH1AGTR1AGTR2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992005161-A1 | 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-04-02 | — | — | WO | disclosed |